← Eichor
Condition: Lung Squamous Cell Carcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Lung Squamous Cell Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carbo
Phase 2 · 34 location(s) · National Cancer Institute (NCI) · NCT05198830APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Ther
Phase N/A · 1 location(s) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT05550961Study of XB010 in Subjects With Solid Tumors
Phase 1 · 20 location(s) · Exelixis · NCT06545331Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT05985655Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Phase 3 · 604 location(s) · National Cancer Institute (NCI) · NCT04181060To Evaluate the Efficacy and Safety of Inhaled Corticosteroids Combined With Bronchodilators and Programmed Death-ligand
Phase N/A · 1 location(s) · Guangzhou Institute of Respiratory Disease · NCT06772454A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With
EARLY_Phase 1 · 1 location(s) · People's Hospital of Quzhou · NCT07647094First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Phase 1 · 10 location(s) · Plexium, Inc. · NCT07284186This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Tor
Phase 1 · 3 location(s) · Zumutor Biologics Inc. · NCT06451497A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers
Phase 1 · 7 location(s) · Light Chain Bioscience - Novimmune SA · NCT05403554GALENOS 1 in Head and Neck, Lung, and Rectal Cancer Patients
Phase N/A · 1 location(s) · Fondazione del Piemonte per l'Oncologia · NCT07511413Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Guangzhou Medical Universit · NCT06383728Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM
Phase 2 · 1 location(s) · Brown University · NCT06974604BAI-BACE for Advanced Lung Squamous Cell Carcinoma
NA · 1 location(s) · Sun Yat-sen University · NCT06377735A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carbop
Phase 3 · 260 location(s) · Hoffmann-La Roche · NCT06793215A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Ce
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07548060At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
Phase 1 · 2 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT03198546A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers
Phase 2 · 1 location(s) · National University Hospital, Singapore · NCT06422403Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced
Phase 2 · 6 location(s) · Sichuan University · NCT06121505Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic H
Phase 1 · 91 location(s) · AstraZeneca · NCT04686305Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanc
Phase 1 · 12 location(s) · Whitehawk Therapeutics, Inc. · NCT07444814A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participan
Phase 3 · 351 location(s) · Mirati Therapeutics Inc. · NCT06875310Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With B
Phase 2/Phase 3 · 61 location(s) · AbbVie · NCT06236438A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet
Phase 2 · 71 location(s) · Bristol-Myers Squibb · NCT07680764Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC H
Phase 2 · 1 location(s) · Avistone Biotechnology Co., Ltd. · NCT07336732Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Tasca Therapeutics · NCT07030257A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Met
Phase 1/Phase 2 · 3 location(s) · GI Innovation, Inc. · NCT07172802A Retrospective Real-World Study Based on RATIONALE-307
Phase N/A · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07478809
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.